About this trial
Colonic Laterally spreading lesions (LSL) =\> 20mm are at high risk to progress to cancer. Overt stigmata of submucosal invasive cancer (SMIC) has been well characterized and includes ulceration and surface pit pattern changes as per the Kudo classification of type V.
In a recent report, risk factors for LSL with SMIC and no overt stigmata (i.e. covert SMIC) were described. Resection of these lesions 'en-bloc' can allow for better histological staging and potentially reduce the need for surgical resection.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
All patients referred for colorectal resection of large laterally spreading lesions in colon.
Can give informed consent to trial participation
Disqualifiers
Previous resection or attempted resection of target adenoma lesion
Endoscopic appearance of invasive malignancy
Age less than 18 years
Pregnancy
Trial design
Parallel
Treatments tested in this trial
Endoscopic Submucosal Dissection
Procedure/SurgeryEndoscopic Submucosal Dissection (ESD) results in en-bloc resection of LSL, regardless of lesion size. This allows for accurate histopathological assessment of SMIC, R0/R1 resection and depth of invasion. ESD is considered a potentially curative for superficial cancers (T1a).
Endoscopic Mucosal Resection
Procedure/SurgeryEMR is the current standard for treating colonic LSL and has been validated to be safe and efficacious. LSLs =\> 20mm are frequently resected piecemeal. Recent research show that resection margin soft coagulation reduces recurrence rates to those similar to en-bloc resections.
Treatment groups
Trial outcomes
Primary outcomes
Rate of surgical referral
Incidence of surgical referral due to non-curative endoscopic resection.
Secondary outcomes
R0 resection rate
Rate of en-bloc resection with clear resection margins.
En Bloc resection rate
Rate of en-bloc resection
Technical success rate
Rate of procedures completed as per protocol
Duration of procedure
Procedure duration in minutes.
Sponsors and contacts
Click on the lead sponsor to view all of their trials.